Le Lézard
Classified in: Health
Subject: MISCELLANEOUS

AgraFlora Organics Completes Construction of Pharma-Grade R&D Laboratory at 51,500 Sq. Ft. GMP Winnipeg Edibles Facility


VANCOUVER, British Columbia, Nov. 21, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. ("AgraFlora" or the "Company") (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF), a growth oriented and diversified international cannabis company, is pleased to announce the Company has completed construction of its pharmaceutical-grade research and development laboratory (the "R&D Laboratory") at its 51,500 square foot GMP edibles manufacturing facility in Winnipeg, Manitoba (the "Winnipeg Edibles Facility").

The Company's 750 square foot, turnkey R&D Laboratory boasts a comprehensive suite of made-to-order cannabinoid-testing and product formulation equipment, including:

The Company's Winnipeg Edibles Facility is also equipped with the ability to formulate and mass-produce cannabinoid-infused fruit/vegetable purees, which conform to the more rigorous Cannabis 2.0 regulations instilled by the Province of Quebec. This unique product development capability will permit the capture of defendable market share of the edibles, topicals and concentrates industry in Canada's second most populous province. As announced on November 8, 2019, AgaFlora intends to initially produce four pectin and/or gelatine based CBD or THC infused gummy SKUs branded with Mesoamerican attributes.

AgraFlora also announces that the Company is in the process of finalizing product formulation, contract manufacturing and R&D agreements with various Canadian Licensed Producers ("LPs"). The Company forecasts that its R&D Laboratory will emerge as a hub for innovation, as well as set the industry's benchmark standard for the industrial-scale production of value-added cannabis products. AgraFlora's R&D Laboratory will be fully operational upon receipt of Health Canada issued research and development license.

AgraFlora's Winnipeg Edibles Facility is equipped with over 30,000 square feet of dedicated edibles production space. Once activated, the Winnipeg Edibles Facility will be operated by a roster of third generation chocolatiers/confectioners and boasts state-of-the-art manufacturing equipment capable of producing an assortment of both cannabinoid/terpene-infused products for medicinal, functional and adult use.

The Winnipeg Edibles Facility is outfitted with fully automated production flows; therefore, reducing associated labour costs and optimizing product throughput, as follows:

Brandon Boddy, Chairman and Chief Executive Officer of AgraFlora stated: "The completion of our pharma-grade R&D Laboratory positions us to secure consistent cash flows as a result of product formulation and contract manufacturing agreements with our peers. We had the corporate foresight to invest in state-of-the-art plant, property and equipment prior to the arrival of cannabis 2.0, of which inherent value continues to be evidenced by growing market demand. Armed with this state-of-the-art facility, we expect to become the unequivocal leader within the highly lucrative cannabinoid-infused edibles and functional food marketplaces."

About AgraFlora Organics International Inc.

AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Services Canada Inc. and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company is also retrofitting a 51,500-square-foot good manufacturing practice ("GMP") edibles manufacturing facility in Winnipeg, Manitoba. AgraFlora has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com.

ON BEHALF OF THE BOARD OF DIRECTORS

Brandon Boddy
Chairman & CEO
T: (604) 398-3147 

For additional information:


AgraFlora Organics International Inc.
Tim McNulty
E: [email protected]
T: (800) 783-6056
 

 

For French inquiries:
Remy Scalabrini, Maricom Inc.
E: [email protected] 
T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which are available at www.sedar.com.

 


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: